Publications by authors named "A E Kieffer"
Article Synopsis
- Patients with high-risk hormone receptor-positive, HER2-negative breast cancer (HR+ BC) show a significant risk of relapse, prompting the need for additional treatment strategies.
- The study analyzed data from the CANcer TOxicities (CANTO) study, involving patients between 2012 and 2022, categorizing them based on various unfavorable features indicating high risk.
- Results indicated that most patients underwent (neo)adjuvant chemotherapy and endocrine therapy; however, many discontinued treatment due to adverse events, with a 5-year survival rate reflecting the need for ongoing management in this patient group.
BMC Infect Dis
September 2024
Article Synopsis
- RSV significantly impacts infants in Spain, leading to many healthcare visits and high costs during their first RSV season.
- A decision-analytic model showed that using nirsevimab as a preventive treatment for all infants could dramatically reduce RSV-related health events and hospitalizations, compared to standard practices.
- Immunizing with nirsevimab could prevent over 97,000 outpatient visits and save about €47.8 million in healthcare costs, highlighting its potential as a cost-effective public health strategy.
Infect Dis Ther
October 2024
Article Synopsis
- - The study evaluates the impact of nirsevimab, a newly approved monoclonal antibody, on reducing RSV-related respiratory illnesses in newborns during their first RSV season in the UK.
- - Using a decision-analytic model, the research predicts that universal administration of nirsevimab can prevent nearly 200,000 RSV cases and save around £77.2 million in healthcare costs compared to current treatment options.
- - The analysis suggests that nirsevimab could offer significant health benefits and economic savings, with a potential value of £243 to £274 per quality-adjusted life year (QALY) saved, based on willingness-to-pay thresholds.
